Publication date: May 10, 2025
The results of our research highlight the ChAdOx1 nCoV-19 vaccine’s ability to modulate harmful responses to the SARS-CoV-2 virus, and therefore to reduce the severity of illness. He said: “These results confirm the efficacy of vaccination and its pivotal role in reducing the harmful consequences associated with COVID-19. The implications of these findings are far-reaching, offering evidence that is fundamental to future vaccine development and pandemic mitigation strategies. Ongoing research is critical as we know the next one is coming but we don’t know which virus or when it will be. ” Notably, the ChAdOx1 nCoV-19 randomised controlled trials received support from UK Research and Innovation, NIHR, Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, among others. It also provides valuable guidance for policymakers and public health experts.
| Concepts | Keywords |
|---|---|
| Global | Chadox1 |
| Pandemic | Covid |
| Professor | Findings |
| Vaccine | Harmful |
| Valuable | Illness |
| Including | |
| Individuals | |
| Ncov | |
| Oxford | |
| Professor | |
| Severe | |
| Severity | |
| Vaccinated | |
| Vaccine | |
| Vaccines |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Spinosad |
| disease | MESH | COVID-19 |
| disease | IDO | immune response |
| disease | IDO | role |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | infections |
| disease | IDO | infection |
| disease | IDO | blood |
| disease | IDO | cell |
| disease | MESH | inflammation |
| disease | MESH | viral infection |